Alameda, CA.—(BUSINESS WIRE)—December 11, 2006—Advanced Cell Technology, Inc.’s (OTCBB: ACTC) Michael West Ph.D., President and Chief Scientific Officer, will deliver the keynote luncheon speech at the New York Society of Security Analysts Conference (NYSSA), on December 12, 2006 at 12:30 PM. William M. Caldwell, IV, Chief Executive Officer, will deliver the company presentation on December 13, 2006 at 1:40 PM. The conference is being held at the NYSSA headquarters located at 1177 Sixth Avenue in New York.
Widely regarded as a leader in the field, prior to founding ACTC, Dr. West organized and managed the research between Geron Corporation (Nasdaq: GERN) and its academic collaborators, James Thomson and John Gearhart, that led to the first isolation of human embryonic stem and human embryonic germ cells. Dr. West will be speaking on the “Emerging Field of Stem Cells”.
William Caldwell will be delivering the company presentation, highlighting Advanced Cell’s leadership and advancement in the stem cell field. The company recently published a paper in Nature regarding the use of embryonic stem cells to rescue visual function in animals, and in August announced an approach to generate human embryonic stem cells that does not destroy the embryo.
A downloadable copy of both presentations will be archived on the company’s website the day of the conference, at www.advancedcell.com/conference-presentations.
Michael West’s presentation is also available from the link below as an audio/ visual webcast.
Click to View Webcast
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Investors: James Carbonara, 212-825-3210
Media: Bill Douglass, 212-825-3210
Financial Communications
Trilogy Capital Partners
Paul Karon, 800-592-6067
Source: Advanced Cell Technology, Inc.
Paul Karon
800-592-6067